Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases

The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema. This study is the first to the investigator's knowledge to compare treatment burden between all three patient groups, which also differ in age and socioeconomic circumstances. The results are of interest to all ophthalmologists who prescribe anti-VEGF treatments, as they show factors which can influence patient adherence und thus the efficacy of said therapies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age Related Macular Degeneration (ARMD) Cardiovascular Diseases Diabetic Macular Edema (DME) Embolism and Thrombosis Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases Retinal Vein Occlusion Retinal Vein Occlusion (RVO) Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hietzing Hospital

Vienna, 1130, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

undergone a minimum of 5 IVT's and had visited the retina clinic for at least 6 months

Exclusion criteria

eye surgery in the preceding six months
notable cognitive impairment, such as dementia
age <18 years

Treatment and study plan

Primary outcomes

Severitiy of subjective treatment burden due to intravitreal anti-VEGF therapy assessed by questionnaire

Time frame: From May 2023 to April 2024

The questionnaire was designed on the basis of the Longitudinal assessment of Adherence Factors to Intravitreal (anti-VEGF) Therapy (LAF-IVT) questionnaire. Patients were interviewed about their perceived treatment burden, their socioeconomic status, and demographic details. Different aspects of treatment burden were graden by the patients as "no", "little", "moderate", "great" or "extreme buden".

Sponsors and collaborators

Lead sponsor

Hospital Hietzing

Other

Collaborators

Scientific fund of the City of Vienna

Registry information

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Apr 7, 2026
Registry last updated: Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed